Red and blue Public Responsibility in Medicine and Research logo.
Login
Donate
  • About Us
    • Who We Are
    • 2025 Annual Report
    • PRIM&R Partners
    • Resources
    • Career Center
    • Ampersand Blog
    • PRIM&R Policy
    • Events Code of Conduct
    • Reporting Misconduct
  • Conference
    • Annual Conference
    • 2026 Student Poster Program
    • Exhibit 2026
    • Past Conferences
    • Ampersand Conference Proceedings
  • Certification
    • Eligibility
    • Exams
    • Recertification
    • CIP Resources
    • CIP Companion
    • CPIA Resources
    • CPIA Companion
    • CIP and CPIA Councils
  • Programs
    • Education at PRIM&R
    • Workshops
    • Courses
    • Webinars
    • Flash Learn
    • Certificates
    • AI in Research Ethics
  • Membership
    • Member Benefits
    • Member Hub
    • Regional Research Ethics Program
  • Understanding Research
    • Research Ethics Timeline
    • Lead the Way
    • Research Ethics Reimagined Podcast
    • People and Perspectives
  • Public Policy
    • Research Ethics in Public Policy
    • Advocacy Toolkit
    • Resources
    • Federal Public Policy Briefings
    • Policy Comments
  • Support Us
    • Donate
    • Ampersand Society
    • Volunteer
    • Sponsor
    • Bookstore

In The News

STAT: Tiny HHS office tasked with protecting research participants’ safety is running on fumes

OHRP was long beset by understaffing. Under Trump, it has lost half its remaining employees By Megan Molteni June 5, 2026 In 2021, the federal office charged with ensuring that the vast research enterprise bankrolled by the Department of Health and Human Services keeps study participants safe, received a report of a death by suicide involving a person enrolled in a study testing a treatment for depression and reduced mobility. Once the Office of Human Research Protections started looking into the death at the New York State Psychiatric Institute, it found problems that spread far beyond that one study, including failures in how the institute’s ethics board reviews proposed research. “We saw, holy smokes, this whole institution has issues,” said Lisa Buchanan, then director of the OHRP’s compliance division. The investigation became all-consuming. “It was probably 60-70% of our time,” she said. The Food and Drug Administration got involved, as did the National Institutes of Health, which had provided grant funding to support the study. OHRP put a hold on all HHS-funded clinical research being conducted at NYSPI, and shortly after, the NIH suspended all grants for human subject research at the institute. Such severe actions are rare in the world of biomedical research. In the months that followed, NYSPI developed a comprehensive corrective action plan that included restructuring its human research protections program under new leadership, implementing additional mandatory training for scientists, and establishing new methods for reporting potential problems. As it began implementing these safeguards, OHRP dropped the ban on human research in October 2024. Two months later, NYSPI signed an agreement with HHS, promising that it would continue to follow through on its plan. HHS in turn agreed to monitor its progress — through reviews of monthly reports and by sending staff from HHS, NIH, and OHRP to conduct at least one on-site visit in the first year of the agreement, according to a copy obtained by STAT. But that required site visit has not taken place, according to three individuals familiar with the matter who spoke on the condition of anonymity because they were not authorized to talk about it. One reason for this lapse in monitoring, they said, is ongoing staffing shortages at OHRP in the wake of the Trump administration’s chaotic downsizing of the federal government that began early last year. Since February 2025, OHRP has lost more than half of its employees, either through reductions in force, resignations, or early retirements. Among the departures were several of the agency’s top leaders, including Buchanan, OHRP director Molly Klote, and longtime deputy director Julie Kaneshiro, who had been with the agency since 2002. OHRP’s advisory committee was also disbanded last spring. Read More

We use cookies to enable essential functionality on our website, and analyze website traffic. By clicking Accept you consent to our use of cookies. Cookies and Privacy Policy.

Your Cookie Settings

We use cookies to enable essential functionality on our website and analyze website traffic. For more information, read our Cookies and Privacy Policy below..

Cookie Categories
Essential

These cookies are strictly necessary to provide you with services available through our websites.

Analytics

These cookies collect information that is used in aggregate and in an anonymized form to help us understand how our website is being used and how effectively our site is performing.